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Abstract
Introduction: Current clinical strategies for treating hormonal breast cancer involve the use of anti-estrogens that
block estrogen receptor (ER)a functions and aromatase inhibitors that decrease local and systemic estrogen
production. Both of these strategies improve outcomes for ERa-positive breast cancer patients, however,
development of therapy resistance remains a major clinical problem. Divergent molecular pathways have been
described for this resistant phenotype and interestingly, the majority of downstream events in these resistance
pathways converge upon the modulation of cell cycle regulatory proteins including aberrant activation of cyclin
dependent kinase 2 (CDK2). In this study, we examined whether the CDK inhibitor roscovitine confers a tumor
suppressive effect on therapy-resistant breast epithelial cells.
Methods: Using various in vitro and in vivo assays, we tested the effect of roscovitine on three hormonal therapy-
resistant model cells: (a) MCF-7-TamR (acquired tamoxifen resistance model); (b) MCF-7-LTLTca (acquired letrozole
resistance model); and (c) MCF-7-HER2 that exhibit tamoxifen resistance (ER-growth factor signaling cross talk
model).
Results: Hormonal therapy-resistant cells exhibited aberrant activation of the CDK2 pathway. Roscovitine at a dose
of 20 μM significantly inhibited the cell proliferation rate and foci formation potential of all three therapy-resistant
cells. The drug treatment substantially increased the proportion of cells in G2/M cell cycle phase with decreased
CDK2 activity and promoted low cyclin D1 levels. Interestingly, roscovitine also preferentially down regulated the
ERa isoform and ER-coregulators including AIB1 and PELP1. Results from xenograft studies further showed that
roscovitine can attenuate growth of therapy-resistant tumors in vivo.
Conclusions: Roscovitine can reduce cell proliferation and survival of hormone therapy-resistant breast cancer cells.
Our results support the emerging concept that inhibition of CDK2 activity has the potential to abrogate growth of
hormonal therapy-resistant cells.
Introduction
The steroid hormone estradiol (E2) plays an important
role in the initiation and progression of breast cancer. Var-
ious biological effects of E2 are mediated through its bind-
ing to distinct estrogen receptors (ER), ERa and ERb, that
differ both functionally and structurally [1,2]. About 70%
of breast cancer patients are ERa positive at the time of
presentation [3]. Upon E2 binding, ERa mediates regula-
tion of target gene transcription and cell cycle progression
via recruitment of co-regulators [2]. Emerging evidence
suggests that ERb decreases cell proliferation, that breast
tumors express low levels of ERb a n dt h a tt h er a t i o
between ERa and ERb is the driving force for tumor cell
proliferation [4]. Current endocrine therapy for ER-posi-
tive breast cancer involves modulating the ER-pathway
using either anti-estrogens (AEs) or aromatase inhibitors
(AIs). Despite the positive effects, de novo and/or acquired
resistance to endocrine therapies frequently occur [5].
Although mechanisms for hormonal therapy resistance
remains elusive, emerging data suggest that ER cross talk
with human epidermal growth factor receptor 2 (HER2)-,
Src-, and AKT-pathways, that alterations in the levels of
ER subtypes, and that deregulation of co-regulator are
major causes of resistance [6-8].
Interestingly, most downstream events in these resis-
tance signaling pathways converge upon modulation of
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which is the upregulation of cyclins E and A, along with
activation of cyclin dependent kinase 2 (CDK2) [9,10].
The cell cycle machinery is also a prime target for both
estrogen and AEs to enhance cell cycle progression or
to induce cell cycle arrest, respectively [11]. CDK2 is
known to aid in cancer cell proliferation by modulating
E2F-pRB pathway [12] and is also shown to enhance
ligand-independent activation of ERa [13,14]. The
expression of RB/E2F target genes, which is tightly con-
trolled by CDK2 activity, is often deregulated and asso-
ciated with worse prognosis for tamoxifen-treated breast
cancer patients [15]. Collectively, these emerging studies
strongly support the concept that CDK2 activity is a cri-
tical component for the generation of a hormone ther-
apy-resistant phenotype and that blocking of CDK2
activity may be useful as a therapeutic strategy for ther-
apy-resistant patients.
(R)-stereoisomer of roscovitine (Seliciclib or CYC202)
is one of the extensively studied CDK inhibitors, both in
vitro and in vivo [16]. Roscovitine is the first, selective,
orally bioavailable inhibitor of CDKs to enter clinical
trials [17] and is currently in phase II trials for B-cell
malignancies, and lung cancer [18]. It predominantly
inhibits CDK2, and has a very short half-life with no
known active metabolites [19]. Earlier studies have
shown that roscovitine promotes accumulation of breast
tumor cells in G2/M phase [20,21], potentiates the anti-
tumor effects of doxorubicin on breast cancer cells [22],
and has a synergistic antitumor effect with irradiation in
a breast cancer xenograft model [23]. Although these
studies suggested that roscovitine may have therapeutic
utility in the management of hormonal therapy-sensitive
breast cancer cells, the utility of roscovitine to suppress
endocrine therapy-resistant breast cancer cells has not
been explored.
In this study, we evaluated the tumor-suppressive
effect of roscovitine using three different breast cancer
models that exhibit resistance to hormonal therapy. Our
findings using in vitro and in vivo xenograft assays
demonstrate that roscovitine has the potential to reduce
growth of all three therapy-resistant cells. Mechanistic
studies revealed that roscovitine actions involve both
blocking of CDK functions as well as down-regulation
of ERa. As roscovitine is currently in clinical trials, our
findings may have a high translational potential, suggest-
ing that roscovitine represents a novel therapeutic drug
for treating therapy-resistant tumors.
Materials and methods
Model cells and reagents
MCF7 cells were purchased from American-type culture
collection (ATCC, Manassas, VA, USA), endocrine-resis-
tant model cells MCF7-HER2 [24], MCF7-tamoxifen
resistant (TamR) [24] and long-term letrozole treated
MCF7ca (MCF7LTLTca) [25] were described. MCF7-
LTLTca and MCF7-TamR cells were cultured in phenol
red free-RPMI medium containing 5% dextran charcoal-
treated serum with either 1 μmol/L of letrozole or 1
μmol/L tamoxifen, respectively. The roscovitine that was
used for the in vitro studies was purchased from Calbio-
chem (San Diego, CA, USA) and that was used for the
in vivo studies was purchased from LC Laboratories
(Woburn, MA, USA). Antibodies for phospho-Rb, phos-
pho-CDK2, and AIB1 were purchased from Cell Signal-
ing (Beverly, MA, USA). The antibody for PELP1 was
purchased from Bethyl Laboratories (Montgomery, TX,
USA). ERa was purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA) and Thermo Fisher Scienti-
fic (Rockford, IL, USA). terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) kit for
apoptosis detection was purchased from (Roche, Man-
nheim, Germany) and Proliferating Cell Nuclear Antigen
(PCNA) antibody was purchased from Vector Lab (Bur-
lingame, CA, USA).
Cell lysis and western blot analysis
Cells were washed with ice cold 1 × PBS and lysis was
conducted using a modified RIPA buffer (150 mM
NaCl, 50 mM Tris-HCl, 50 mM NaF, 5 mM EDTA,
0.5% (wt/vol) sodium deoxycholate and 1% Triton X-
100) containing phosphatase and protease inhibitors.
Lysates were run on either 7% or 8% SDS-PAGE. Wes-
tern blot analysis was performed with phospho- and
total antibodies. For protein degradation analysis, model
cells were pretreated with MG132 (5 μM) for one hour
prior to treatment with 20 μM roscovitine.
Cell proliferation assay
The cell proliferation rate was measured in a 96-well,
flat, clear-bottom, opaque-wall microplates using Cell
Titer-Glo Luminescent Cell Viability Assay (Promega,
Madison, WI, USA). Model cells (2 × 10
3)w e r ep l a t e d
in each well and cultured for 24 hours before treatment
with or without various doses of roscovitine for another
72 hours. Total ATP content as an estimate of total
number of viable cells was measured by luminescence-
based assay using automatic Fluoroskan Luminometer
(Thermo Scientific Waltham, MA, USA). Roscovitine
was dissolved in dimethyl sulfoxide (DMSO) as 2.8 mM
stock solution and stored as aliquots at -20°C. All ros-
covitine treatments were performed in phenol red-free
medium as described [26].
Clonogenic assay
Model cells were plated in six-well plates at a density of
1×1 0
3 cells per well in triplicate and treated with or
without 10 μM roscovitine for seven days. After three
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with 0.5% crystal violet. Image acquisition was con-
ducted using a digital camera.
Flow cytometry
Model cells were plated in 100 mm plates and treated
with or without 20 μM roscovitine for 24 hours. Cells
w e r et r y p s i n i z e da n dh a r v e s t e di n1×P B S ,f o l l o w e db y
fixation in ice cold 70% ethanol. Staining was done with
am i x t u r eo f5 0μg/mL propidium iodide and 50 μg/mL
RNase A. Cell cycle status was quantified by using a
FACS-Calibur flow cytometer.
Quantitative RT-PCR analysis
Model cells were plated in 100 mm plates and treated with
or without roscovitine (20 to 30 μM) for 24 hours. Cells
were harvested with Trizol Reagent (Invitrogen, Carlsbad,
CA, USA) and total RNA was isolated according to the
manufacturer’s instructions. cDNA synthesis was done
using Superscript III RT-PCR kit (Invitrogen, Carlsbad,
CA, USA). Real-time PCR was done using a Cepheid
Smartcycler II (Sunnyvale, CA, USA) with specific real-
time PCR primers for the ERa (ESR1-F: 5’AGAGG-
GAAAGTAGGGCAGAA 3’ and ESR1-R: 5’TGGGAAAT-
GAAGAAGAGCTG 3’). Results were normalized to actin
transcript levels and the difference in fold expression was
calculated using delta-delta-CT method.
In vivo xenograft assays
All animal experiments were performed after obtaining
University of Texas Health Sciences Centre at San Anto-
nio (UTHSCSA) institutional animal care committee
(IACUC) approval and the animals were housed in
accordance with UTHSCSA institution’sp r o t o c o lf o r
animal experiments. Model cells (5 × 10
6) cells mixed
with an equal volume of Matrigel were implanted sub-
cutaneously into the flanks of six to seven-week-old
female nude mice as described [27]. For MCF7-HER2
x e n o g r a f t s ,n u d em i c ew e r ea l s os u b c u t a n e o u s l y
implanted with estrogen pellets (Innovative Research,
Sarasota, FL, USA) [28]; whereas nude mice with
MCF7-TamR and MCF7-LTLTca xenografts were given
subcutaneous injection of tamoxifen (100 μg/day/mice)
or Δ4-androstenedione (100 μg/day/mice), respectively,
as described [29]. Roscovitine treatment was initiated
after three weeks of inoculation when tumors reached
measurable size. Roscovitine suspension was prepared in
50 mM HCl solution as described earlier [30] and admi-
nistered orally at a dose of 100 mg/kg body weight
(three times a day) for 10 consecutive days (total 30
doses). Tumor volumes were measured with a vernier
caliper at weekly intervals. After the 25
th day, the mice
were euthanized, and the tumors were removed,
weighed and processed for immunohistochemistry (IHC)
staining. Tumor volume calculation was performed
using modified ellipsoidal formula: tumor volume =1 / 2
(L × W
2), where L is the longitudinal diameter and W is
the transverse diameter [27]. Body weight was measured
at weekly intervals to rule out the drug toxicity. Student
t-test was used to assess the statistical difference
between control and roscovitine-treated groups. The
level of significance was set at P < 0.05.
Immunohistochemistry and TUNEL assay
IHC analysis was performed as described [27]. The dilu-
tion of the PCNA antibody used for IHC was 1 in 100.
After washing with 1 × PBST, slides were further incu-
bated in DAKO universal secondary LINK solution for
30 minutes and horseradish peroxidase-labeled streptavi-
din for 20 minutes at room temperature. Successful
staining was visualized using the DAB substrate (Vector
Lab, Burlingame, CA, USA), followed by counterstaining
using Mayer’s hematoxylin (Vector Lab, Burlingame,
CA, USA). TUNEL staining was performed following
manufacturer’s instructions (Roche, Indianpolis, IN).
Results
Roscovitine suppresses proliferation and survival of
therapy-resistant cells
To examine whether deregulation of CDK2 signaling
occurs in therapy-resistant cells, we initially determined
the status of CDK2 activation in therapy-resistant model
cells that exhibit therapy resistance to AE (MCF7-HER2,
and MCF7-TamR) and AI (MCF7LTLTca). CDK2 acti-
vation was determined by measuring the levels of phos-
pho-CDK2 (T160) by using western blot analysis.
Phospho-CDK2 levels were enhanced in all three ther-
apy-resistant model cells but not in the hormone-sensi-
tive breast cancer cells such as MCF7 and ZR-75-1
( F i g u r e1 a ) .W et h e nt e s t e dw h e t h e rr o s c o v i t i n es u p -
presses the growth of therapy-resistant cells by exposing
them to increasing concentrations of roscovitine and
determined their rate of proliferation using a lumines-
cence-based cell proliferation assay. Hormonal therapy-
sensitive MCF7 cells were used as a positive control and
these cells had a dose-dependent reduction in cell prolif-
eration. Interestingly, all the three endocrine-resistant
cells also had concomitant reductions in cell prolifera-
tion upon roscovitine treatment (Figure 1b) with 50% or
more reduction in cell proliferation (IC50)a tad o s e
range of 20 to 30 μM. Compared with MCF7 cells, resis-
tant cells were more sensitive to 30 μM roscovitine. We
next examined whether, roscovitine affects clonogenic
survival of endocrine-resistant cells by using an in vitro
clonogenic survival assay. We treated therapy-resistant
models cells with 20 μM roscovitine for seven days and
measured their clonogenic ability after three weeks (Fig-
ure 1cupper panel). Compared with untreated cells,
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reduction in the colony formation potential and LTLTca
cells had about 4% colony formation (Figure 1clower
panel). Overall, these results suggest that roscovitine has
the potential to suppress the proliferation and survival
potential of endocrine-resistant cells.
Roscovitine arrests the cell cycle in endocrine-resistant
cells
Previous studies found that roscovitine has the potential
to perturb cell cycle progression in various cell lines
[26]. To evaluate whether roscovitine promotes cell
cycle arrest in endocrine-resistant cells, we treated three
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Figure 1 Effect of roscovitine on cell proliferation and survival of endocrine-resistant cancer cells. (a) Total cellular lysates from control
and therapy-resistant model cells were subjected to western blotting using phosphor cell cycle dependent kinase (CDK) 2 antibody. Graph
shows densitometry measurements of phosCDK2 protein bands relative to total CDK2 in each cell line. (b) Model cells were treated with or
without roscovitine and cell proliferation was determined at indicated time points by using the Cell Titer Glo assay. (c) Model cells were treated
with or without roscovitine and clonogenic survival was determined. Representative figures and quantitative analysis of survival was shown.
Statistical significance was determined by student’s t-test. P, P value; * P < 0.05; ** P < 0.01. Con, control; Phos, phospho; ROS, roscovitine.
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hours. Compared with their untreated cells, roscovitine-
treated MCF7, MCF7-TamR, and MCF7-HER2 cells had
substantial more cells containing 4N DNA content (G2/
M phase) and concurrently less cells in the G1 phase
(Figure 2a to 2f). However, 74% of roscovitine-treated
LTLTca cells accumulated in the G1 phase and 48% of
the untreated LTLTca cells accumulated in the G1
phase (Figure 2g and 2h). Collectively, these results sug-
gest that roscovitine has potential to block cell cycle
progression of endocrine therapy-resistant cells and pre-
ferentially arrest them at the G2/M or G1 phase of cell
cycle.
Roscovitine down regulates key cell cycle regulators and
ERa levels
As roscovitine induced cell cycle arrest in endocrine-
resistant cells, we next examined the expression of key
cell cycle regulators in roscovitine-treated endocrine-
resistant cells. As expected, roscovitine treatment
reduced CDK2 activity as detected by less CDK2
threonine 160 phosphorylation in all three resistant cells
and also in MCF7 cells (Figure 3a). Further, the level of
phospho-Rb, a well-known substrate of CDK2, was
reduced after roscovitine treatment, confirming the
down regulation of CDK2 axis in roscovitine-treated
cells (Figure 3a). Roscovitine-treated endocrine-resistant
cells also had reductions in the levels of cyclin D1 with
no or little change in cyclin A2. Interestingly, roscov-
itine treatment specifically down regulated the ERa iso-
form expression but had little effect on ERb expression
(Figure 3a). Furthermore, roscovitine down regulated
co-activators of ERa such as AIB1 and PELP1, which
also play predominant roles in hormonal cell cycle pro-
gression and resistance [31,32] (Figure 3a). As ERa
expression is regulated at both transcriptional and trans-
lational levels, we examined whether the down regula-
tion of ERa is due to transcriptional or post-
translational effects of roscovitine. We found signifi-
cantly less ERa mRNA levels in roscovitine-treated
MCF7 and therapy-resistant cells than in their untreated
counterparts (Figure 3b). Further, treatment of cells
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Figure 2 Roscovitine modulates cell cycle status of endocrine-resistant cancer cells. (a, c, e, g) Control cells and/or ( b ,d ,f ,h )cells that
were treated with roscovitine were subjected to flow cytometry. The percentage of cells in each cell cycle phase is depicted on the top of
corresponding G1, S, and G2/M peaks. ROS, roscovitine.
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tially rescue the degradation of ERa with roscovitine
treatment (Figure 3c). These results suggest that roscov-
itine can block both CDK2 signaling axis as well as
down regulate specific components of ERa signaling
axis.
Therapeutic efficacy of roscovitine on xenografts
generated from endocrine-resistant model cells
To examine whether roscovitine inhibits growth of ther-
apy-resistant cells in vivo, we used a nude mice-based
xenograft assay. After three weeks of implantation and
when tumors reached measurable size, roscovitine or
vehicle was given orally at a dose of 100 mg/kg/mice/
day, three times a day for 10 consecutive days. Tumor
volume was measured every week and after 25 days the
last treatment, mice were euthanized. For all three mod-
els, roscovitine-treated mice had significantly smaller
tumor volumes (Figure 4a to 4c) and smaller tumor
sizes (Figure 4d). No toxicities were observed in beha-
vioral changes, such as eating habits and mobility, in
animals treated with roscovitine and mouse weights
were not significantly different between control and ros-
covitine-treated groups (data not shown). IHC analysis
for PCNA, a well-established proliferation marker,
revealed less PCNA staining in all the roscovitine-
treated tumors (Figure 5a). A reduction in the PCNA
index with roscovitine treatment was more significant in
MCF7LTLTca xenografts than in MCF7-TamR and
MCF7-HER2 xenografts (Figure 5b). Furthermore, com-
pared with untreated xenografts, roscovitine-treated
xenografts had greater levels of apoptosis when assayed
using TUNEL staining (Figure 5c). IHC analysis using
ERa-specific antibody revealed less ERa staining in ros-
covitine-treated cells than in the untreated cells (Figure
5d). Overall these results suggest that roscovitine can
suppress cell proliferation of therapy-resistant cells and
lead to apoptosis.
Discussion
Breast cancer is the most common cancer among
women in the USA and patients with ERa-positive
tumors greatly benefit from existing hormonal therapies
using AEs and AIs. [33-36]. However, many patients
exhibit de novo or acquired resistance to hormonal
therapies. This resistance represents a major clinical
problem. Emerging findings suggest that deregulation of
cell cycle components such as CDK2 axis has the poten-
tial to contribute both to cell cycle progression and to
endocrine resistance [11]. In this study, we explored the
hypothesis that targeting the CDK2 axis using roscov-
itine will have therapeutic benefit. Using three model
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Figure 3 Roscovitine treatment suppresses expression of key regulators of cell cycle and the ER a-signaling axis. (a) The model cells
MCF7, MCF7-TamR, MCF7-HER2, and MCF7-LTLTca were treated with roscovitine and the status of cell cycle regulators and the estrogen
receptor (ERa) signaling proteins was analyzed by western blotting. (b) MCF7, MCF7-Tam, MCF7-LTLTca, and MCF7-HER2 were treated with
roscovitine and the levels of ERa transcripts were determined by quantitative RT-PCR. (c) Model cells were pre-treated with the proteosomal
inhibitor MG132 and then subjected to roscovitine treatment. ERa status was determined by western blotting of total lysates. Actin was used as
loading control. Con, control; ROS, roscovitine.
Nair et al. Breast Cancer Research 2011, 13:R80
http://breast-cancer-research.com/content/13/4/R80
Page 6 of 11cells that exhibit endocrine therapy resistance, we found
that (1) therapy-resistant cells exhibit greater CDK2
activation; (2) roscovitine treatment decreased CDK2
activity and promoted G2/M or G1 accumulation of
resistant cells; (3) roscovitine treatment significantly
reduced proliferation of the resistant cells; (4) roscov-
itine preferentially down regulated the ERa isoform and
its associated signaling components; and (5) preclinical
xenograft-based studies found roscovitine had a thera-
peutic efficacy by attenuating the growth of resistant
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Figure 4 Roscovitine exerts a tumor suppressive effect on endocrine-resistant breast cancer xenografts. Nude mice were subcutaneously
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signaling confers a growth advantage to resistant cells
and that roscovitine treatment represents a feasible
strategy for therapeutic targeting of hormonal therapy
resistance.
Tumor cells exhibit oncogenic addiction. Recent stu-
dies suggest that interphase CDKs (CDK4, CDK2) are
only essential for proliferation of tumor cells and selec-
tive CDK inhibition may provide therapeutic benefit [37].
Previous studies demonstrated the potential of roscov-
itine to abrogate cell proliferation and to induce cell
cycle arrest in both ER-positive cells [21,26,38] and ER-
negative cells [39]. In this study, we demonstrated that
roscovitine exhibited a profound growth inhibitory effect
on hormone-resistant model cells. Roscovitine treatment
promoted G2/M arrest in MCF7-TamR and MCF7-
HER2 cells and arrested in LTLTca cells in the G1 phase.
These findings are in agreement with the findings from
published studies that concluded roscovitine has the
potential to arrest cell cycle predominantly at G2/M
phase and occasionally in the G1 phase [22,38,40,41].
The differential effect of roscovitine on cell cycle status
in LTLTca compared with TamR and HER2 cells is cur-
rently unknown, but we speculate the difference may lie
in differential activation of cell cycle checkpoints in these
model cells. Utility of roscovitine against letrozole-resis-
tant breast cancer cells have recently been demonstrated
[42] and our data strongly corroborate this study.
Activation of the CDK2 axis is considered a vital end
point of various molecular pathways leading to
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Page 8 of 11hormone-therapy resistance [11]. Cyclin E, an activator
of CDK2, when ectopically over-expressed is able to
abrogate the anti-proliferative actions of tamoxifen on
breast cancer cells [9] and is also shown to be a good
indicator for endocrine-therapy failure [43,44]. Recent
studies showed that cyclin E can undergo proteolytic
cleavage to create low molecular weight (LMW) cyclin E
variants [45] and these LMW cyclin E variants lacking
the amino-terminus could significantly augment the
tamoxifen therapy resistance by activating CDK2 func-
tions [46]. LMW cyclin E is also reported to abrogate
the anti-proliferative activity of the AI letrozole [42].
Overexpression of cyclin A in breast cancer also signifi-
cantly correlates with poor outcome in tamoxifen-trea-
ted patients [47]. Down regulation of CDK inhibitors
(p21 and p27) have been implicated in the development
of hormone therapy resistance [48,49]. In this study, we
show that roscovitine, a potent inhibitor of CDK2, can
curb the growth of therapy-resistant breast cancer cells
and to down regulate expression of ERa. As deregula-
tion of the cell cycle machinery and ER signaling both
contribute to hormonal therapy resistance, a roscovitine
treatment regime that suppresses both these pathways
could serve as a double-edged sword to interfere with
the hormonal therapy-resistant mechanisms.
Cell cycle regulators cyclins and CDKs are the key
proteins that aid in cell proliferation by modulating the
E2F-RB pathway [12]. Earlier studies that showed func-
tional ablation of retinoblastoma protein (pRb) leads to
activation of CDK2 in breast cancer [15,50] and concor-
dantly, that deregulation of E2F transcription factor tar-
get genes associated with poor prognosis [51]. Our
results suggested that roscovitine can reduce phosphory-
lation of Thr160 in CDK2 (a marker of CDK2 activa-
tion), reduce phosphorylation of pRb (a well-known
substrate of CDK2) at Ser795, and reduce levels of
cyclin D1 in therapy-resistant cells. The ability of ros-
covitine to reduce pRb phosphorylation and to alter the
status of cyclin D1, suggest that roscovitine therapy may
have therapeutic benefit on clinical cases with CDK2
activation and deregulation of E2F functions.
Cross talk between the cell cycle machinery and ER
pathways has been well documented in the context of
endocrine resistance [11]. CDKs are known to potenti-
ate ER functions in AE-resistant cells [13] and CDK2
activity significantly correlates with poorer five-year
relapse-free survival in patients [52]. Interestingly, in
our study, in vitro roscovitine treatment reduced the
expression of both ERa and ER co-regulators such as
AIB1 and PELP1, which are commonly implicated in
therapy resistance [31,32]. Our findings suggest that
the reduction in ERa levels in the resistant cells is due
to both transcriptional and post-translational effects by
roscovitine. Our data corroborate data from a recent
study that demonstrated a reduction in ERa levels in
MCF7 cells after roscovitine treatment, which possibly
occurred through the inhibition of CDK7 [53]. As
many endocrine therapy-resistant cells retain expres-
sion and functionality of ERa, the ability of roscovitine
to down regulate the ERa axis, may also have contrib-
uted to its ability to curb the progression of the resis-
tant cells.
(R)-roscovitine is currently in early clinical trials to
examine its effects on treating non-small cell lung can-
cer and advanced solid tumors [12]. The oral bioavail-
ability of (R)-roscovitine is a great advantage for its
possible future clinical use. In this study, we tested effi-
cacy of roscovitine in vivo by using a xenograft trans-
plantation assay. Our data suggest that roscovitine has
strong tumor suppressive effects on endocrine-resistant
xenograft tumors. To avoid possible side effects of ros-
covitine, we chose a rather moderate dose (100 mg/kg)
of the drug; a few other studies used 400 mg/kg roscov-
itine [22]. IHC analysis of tumors revealed a significant
decrease in proliferation along with an increase in apop-
tosis. Our data corroborate data from other studies that
demonstrated the apoptotic potential of roscovitine
[39,54] and in turn suggest that multiple pathways are
responsible for roscovitine-induced tumor suppressive
effects.
Conclusions
Our results support the concept that inhibition of CDK2
activity has the potential to abrogate growth of hormo-
nal therapy-resistant cells. Further, the results from this
study provide strong in vitro and in vivo evidence that
roscovitine confers a tumor-suppressive effect on endo-
crine therapy-resistant breast tumor cells by inhibiting
CDK functions and altering expression of ERa and ER-
coregulators, and by promoting apoptosis. Future studies
are needed to examine whether roscovitine treatment
can be used to treat advanced and therapy-resistant
breast cancer and whether roscovitine treatment can
complement the existing therapies.
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